452 zoekresultaten voor “drug” in de Publieke website
-
Modern Drug Discovery
How are new drugs developed? This question is central to the Minor Modern Drug Discovery (MDD), which covers the entire trajectory from disease to drug molecule and vice versa. The various research groups involved offer a complementary and interdisciplinary perspective by connecting the diverse subjects…
-
Drug Discovery & Safety
In het onderzoeksprogramma Drug Discovery & Safety zijn we geïnteresseerd in de werkzaamheid en veiligheid van nieuwe medicijnen en nieuwe manieren om deze aspecten te bepalen. Daarvoor combineren we geavanceerde imaging en high-throughput screening technieken met computationele aanpakken zoals chem-…
-
Photo-activated drug delivery systems
O-Nitrobenzyl groepen worden veel gebruikt als moleculaire beschermgroepen die je met licht kunt verwijderen.
-
Drug Discovery and Safety (MSc)
In deze opleiding ontwikkel je je onderzoek skills en verbreed je je kennis over de meest moderne en geavanceerde technieken die je nodig hebt als onderzoeker op het gebied van target finding en het ontwerp en de synthese van nieuwe geneesmiddelen.
-
Mechanistic modelling of drug target binding kinetics as determinant of the time course of drug action in vivo
Drug-target binding kinetics determine the time course of the central event in pharmacotherapy: Drug-target interaction.
-
PhD candidate combinatorial drug discovery with macrocycles
Wiskunde en Natuurwetenschappen, Leiden Academic Centre for Drug Research (LACDR)
-
Dynamics of TNFalpha signaling and drug-related toxicity
In previous studies at our laboratory it was demonstrated that drug exposure of HepG2 cells can lead to an altered TNFα-induced NF-κB oscillatory phenotype, concurrent with a synergistically increased sensitivity for TNFα-induced apoptosis.
-
Leiden Academic Centre for Drug Research
Het ontwikkelen van nieuwe medicijnen is een complex proces waarbij veel partijen samenwerken. De onderzoekers van het LACDR zetten zich dagelijks in voor nieuwe, betere, efficiëntere en makkelijker produceerbare medicijnen. Het instituut werkt nauw samen met het LUMC, met bedrijven op het Leiden Bio-Science…
-
Ginsenosides as selective glucocorticoid drugs: agonists, antagonists, and prodrugs
Glucocorticoids are potent anti-inflammatory drugs widely used clinically to treat various inflammatory and immune conditions. However, two main clinical problems limit their use. GCs trigger severe side effects and they induce acquired glucocorticoid resistance, especially during chronic systemic treatment…
-
Advanced in vitro models for studying drug induced toxicity
Promotor: B.van de Water, Co-promotor: L.S.Price
-
To explore the drug space smarter: Artificial intelligence in drug design for G protein-coupled receptors
Over several decades, a variety of computational methods for drug discovery have been proposed and applied in practice. With the accumulation of data and the development of machine learning methods, computational drug design methods have gradually shifted to a new paradigm, i.e. deep learning methods…
-
Activity-based protein profiling in drug discovery
In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.
-
Reverse engineering of drug induced QT(c) interval prolongation: Towards a systems pharmacology approach
Promotor: M. Danhof Co-promotor: O.E. Della Pasqua
-
Computational Approaches to Disease, Signaling and Drug Targets
The Minor Computational Approaches to Disease, Signaling and Drug Targets (CADSDT) is focused on fundamental scientific research required for discovery of new drug targets and development of new drugs.
-
mRNA and drug delivery with lipid-based nanoparticles
This thesis focuses on the application of lipid-based nanomedicine in drug delivery, including small molecular antitumor drugs and biomacromolecules including mRNA, and evaluates their biological performance.
-
Proteins in harmony: Tuning selectivity in early drug discovery
This thesis describes the importance of being able to control the selectivity of potential drug candidates.
-
Microengineered Human Blood Vessels For Next Generation Drug Discovery
Heart failure is a major health care problem with high mortality.
-
Novel target engagement biomarkers for better drug candidates
M van der Stelt
-
Prediction of spatial-temporal brain drug distribution with a novel mathematical model
A novel mathematical model describes spatial-temporal drug distribution within one or more brain units, which are cubic representations of a piece of brain tissue with brain capillaries at the edges.
-
Pharmacogenomics in drug development: implementation and application of PKPD model based approaches
Promotor: Prof.dr. M. Danhof, Co-Promotor: J. de Jongh
-
Towards improved drug action : target binding kinetics and functional efficacy at the mGlu2 receptor
During the course of drug discovery translational steps are made.
-
vesicles: An efficient membrane biophysical tool and its application in drug delivery studies
Promotor: A. Kros
-
A chemical biology approach for targeting of ligand-drug conjugates
Promotores: H.S. Overkleeft, G.A. van der Marel, Co-Promotor: R.G. Boot
-
Systems pharmacokinetic models to the prediction of local CNS drug concentrations in human
Clinical development of drugs for central nervous system (CNS) disorders has been particularly challenging and still suffers from high attrition rates.
-
Time is of the essence: investigating kinetic interactions between drug, endogenous neuropeptides and receptor
Promotor: A.P. IJzerman Co-promotor: L.H. Heitman
-
namic Relationships of Central Nervous Systems Active Dopaminergic Drugs
Discovery and development of Central Nervous System (CNS) drugs is hampered by high attrition rates.
-
How to scale clearance from adults to children for drugs undergoing hepatic metabolism?
The aim of this thesis is to expedite and ensure the systematic accuracy of clearance scaling from adults to paediatric patients, with a special focus on drugs undergoing hepatic metabolism.
-
Drug-target residence time: a case for the adenosine A1 and A2A receptors
Promotor: A.P.IJzerman, Co-Promotor: L.H. Heitman
-
Pharmacogenomics in Drug Development: Implementation and Application of PKPD Model Based Approaches
Model based approaches, integrating physiological parameters or linking exposure with response, are powerful tools to quantify and evaluate the impact of genetic differences that are reflected as variability of drug exposure and/or clinical response(s). This thesis “Pharmacogenomics in Drug Development: …
-
Personalised pharmacotherapy in paediatric epilepsy : the path to rational drug and dose selection
The path to rational drug and dose selection
-
The impact of obesity on the pharmacokinetics of drugs in adolescents and adults
Promotores: C.A.J. Knibbe; J.N. van den Anker, Co-promotores: H.P.A. van Dongen; B. van Ramshorst
-
Transforming data into knowledge for intelligent decision-making in early drug discovery
Promotor: A.P.IJzerman Co-promotor: A. Bender
-
Systems microscopy to unravel cellular stress response signalling in drug induced liver injury
Promotor: B. van de Water
-
quantification of growth hormone secretion : application of model-informed drug development in acromegaly
Growth hormone profiles are pulsatile and highly variable between individuals, limiting the implementation of mathemathical models to quantify an individual's secretion.
-
Image-based phenotypic screening for breast cancer metastasis drug target discovery
The main aim of this thesis was to unravel the signaling and regulatory networks that drive tumor cell migration during breast cancer metastasis.
-
Gene networks-based mechanistic assessment of drug-induced organ toxicity: a focus on liver and kidney
Drug induced organ toxicity is the main problem of the drug development and drug usage in the clinic. The liver and kidneys are the most sensitive organs towards drug induced toxicity.
-
system-based pharmacology approach to predict developmental changes in renal drug clearance in children
Promotores: Prof.dr. C.A.J. Knibbe, Prof.dr. M. Danhof, Prof.dr. K. Allegaert (Leuven)
-
and flow of data: connecting large datasets with machine learning in a drug discovery envirionment
This thesis focuses on data found in the field of computational drug discovery. New insight can be obtained by applying machine learning in various ways and in a variety of domains. Two studies delved into the application of proteochemometrics (PCM), a machine learning technique that can be used to…
-
Development of a Kidney-on-a-Chip Model for Compound Screening and Transport Studies
Pharmaceutical companies, governments and the general public have become increasingly aware that animal models used in drug testing lack vital aspects to serve as an accurate representation of human biology. As models of the human body should become more physiologically relevant, animal models no longer…
-
Psycholoog schrijft nuchter boek over psychedelische drugs
Psychedelische drugs zoals paddo’s en LSD worden door de één omarmd, en door de ander gezien als levensgevaarlijk. Cognitief psycholoog Michiel van Elk dook in de wereld van de psychedelica en schreef er een opvallend nuchter boek over. ‘Zonder ervaring uit eerste hand vond ik mijn verhaal niet comp…
-
Cancer Drug Discovery Initiative maakt nieuwe therapieën tegen kanker mogelijk
Het Antoni van Leeuwenhoek/Nederlands Kanker Instituut, het Leids Instituut voor de Chemie en het Pivot Park Screening Centre gaan kennis en infrastructuur delen in het Cancer Drug Discovery Initiative. Vrijdag 11 oktober tekenden ze een letter of intent.
-
Publiekssymposium over psychologische effecten van geneesmiddelen en recreatieve drugs
Heeft het gebruik van medicijnen en drugs invloed op mijn persoonlijkheid? Wat zijn de (langere-termijn) gevolgen van de leerpil 'Ritalin'? Kunnen (party)drugs en medicijnen met rijden in het verkeer samengaan? Wat doen verslavende stoffen met mijn brein?
-
Erik Danen benoemd tot hoogleraar Cancer drug target discovery
Met ingang van 1 april 2018 is Erik Danen benoemd tot hoogleraar Cancer drug target discovery bij het Leiden Academic Centre for Drug Research (LACDR). Zijn vakgebied is celbiologie van kanker, waarin hij zich richt op de achterliggende mechanismen bij uitzaaiingen en resistentie voor behandelingen.
-
Triblock polypept(o)ides for siRNA delivery: unique polymeric designs for versatile carrier systems
Utilizing the polymeric platform of polypept(o)ides, this thesis describes synthesis and investigation of novel triblock copolymers to obtain carrier systems with multiple compartments for efficient siRNA delivery. Although the individual microstructure of nanoparticles differs depending on the polymeric…
-
Evani Lachmansingh
Wiskunde en Natuurwetenschappen
e.t.lachmansingh@liacs.leidenuniv.nl | +31 71 527 2727
-
Alexander Kros
Wiskunde en Natuurwetenschappen
a.kros@chem.leidenuniv.nl | +31 71 527 4234
-
Targeted Therapy for Triple-Negative Breast Cancer
The research described in this thesis focused on identifying novel drug targets and synergistic combinations for triple-negative breast cancer (TNBC), a virulent subtype of breast cancer with a dismal prognosis and limited therapeutic options.
-
Discovery of antibiotics and their targets in multidrug-resistant bacteria
Global healthcare is on the verge of an antibiotic availability crisis as bacteria have evolved resistance to nearly all known antibacterials. Identifying new antibiotics that operate via novel modes-of-action is therefore of high priority.
-
Promoveren aan twee universiteiten op drugsmisbruik
Stimulerende drugs als khat en cocaïne hebben negatieve impact op dagelijkse handelingen als autorijden, werk of sociaal gedrag. Dat komt door beschadiging van controlefuncties in de hersenen. Psycholoog Manuel Ruiz draagt bij aan beter begrip en behandeling van drugsmisbruik. De Spanjaard Ruiz promoveert…
-
Medical Delta café: translation models for drug discovery and development, 8 oktober 2013
Onze gemiddelde leeftijd gaat omhoog en de behoefte naar goede gezondheidszorg wordt steeds groter. Nieuwe medicijnen moeten op de markt komen maar kosten voor de ontwikkeling daarvan moeten omlaag. Tijdens het Medical Delta café op 8 oktober presenteren o.a. dr. Leo Price, dr. Jan de Sonneville en…